A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors
Study Number: RAIN-3202 (JIT)
Study Summary:
Phase 2, multicenter, single-arm, open-label basket study designed to evaluate the safety and efficacy of milademetan in patients with advanced or metastatic solid tumors refractory or intolerant to standard-of-care therapy that exhibit wild-type (WT) TP53 and MDM2 copy number (CN) ≥ 8 using prespecified biomarker criteria.
Status: Open
Study Coordinator(s)
- Navigator Ashton, 309-243-3611 atodd@illinoiscancercare.com
- Navigator Carrie, 309-243-3621 cgeoffroy@illinoiscancercare.com
- Navigator Angie, 309-243-3613, aearles@illinoiscancercare.com
